Trispecific T cell engagers in hematological malignancies: Advancing beyond bispecific antibodies.

The success of bispecific T cell engagers (BiTEs) in hematological malignancies has catalyzed the development of trispecific antibodies that simultaneously target 3 molecular entities. These next-generation immunotherapeutics address the key limitati…

Preview only. Read the full abstract at the source